{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:26:46Z","timestamp":1790717206519,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jdcr.2026.02.049","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:10:04Z","timestamp":1775182204000},"page":"52-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Successful methotrexate rescue following antibody-mediated infliximab failure for treatment-refractory hidradenitis suppurativa"],"prefix":"10.1016","volume":"72","author":[{"given":"Richard","family":"Rookwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahidul","family":"Islam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Schiraldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana","family":"Salloum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5536-2873","authenticated-orcid":false,"given":"Kristina","family":"Campton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ciocon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2026.02.049_bib1","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab for hidradenitis suppurativa","volume":"375","author":"Kimball","year":"2016","journal-title":"N Engl J Med"},{"issue":"10378","key":"10.1016\/j.jdcr.2026.02.049_bib2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials","volume":"401","author":"Kimball","year":"2023","journal-title":"Lancet"},{"issue":"10443","key":"10.1016\/j.jdcr.2026.02.049_bib3","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomized, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimball","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jdcr.2026.02.049_bib4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/ijd.16565","article-title":"Adalimumab efficacy is inversely correlated with body mass index (BMI) in hidradenitis suppurativa","volume":"62","author":"Nosrati","year":"2023","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2026.02.049_bib5","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2025.05.1418","article-title":"Predictors of drug survival of biologics in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"93","author":"Rayner","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jdcr.2026.02.049_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/ecco-jcc\/jju026","article-title":"High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacy","volume":"9","author":"Hendler","year":"2015","journal-title":"J Crohns Colitis"},{"issue":"9194","key":"10.1016\/j.jdcr.2026.02.049_bib7","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jdcr.2026.02.049_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15691","article-title":"Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis","volume":"35","author":"Shih","year":"2022","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1016\/j.jdcr.2026.02.049_bib9","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","article-title":"High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa","volume":"82","author":"Ghias","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jdcr.2026.02.049_bib10","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1007\/s10620-024-08515-5","article-title":"Reactive immunomodulator addition to infliximab monotherapy restores clinical response in inflammatory bowel disease: a meta-analysis","volume":"69","author":"Lowell","year":"2024","journal-title":"Dig Dis Sci"},{"issue":"1","key":"10.1016\/j.jdcr.2026.02.049_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s00384-023-04349-1","article-title":"Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease","volume":"38","author":"Stallhofer","year":"2023","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"10.1016\/j.jdcr.2026.02.049_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/09546634.2012.683767","article-title":"Long-term efficacy of infliximab in hidradenitis suppurativa","volume":"23","author":"Paradela","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jdcr.2026.02.049_bib13","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.jaad.2025.11.040","article-title":"Risk of immunogenicity during infliximab therapy in hidradenitis suppurativa compared with other chronic inflammatory diseases: a retrospective monocentric cohort","volume":"94","author":"Barral","year":"2026","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.jdcr.2026.02.049_bib14","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.cgh.2019.03.037","article-title":"Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases","volume":"17","author":"Papamichael","year":"2019","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626001463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512626001463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:27:16Z","timestamp":1785281236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512626001463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":14,"alternative-id":["S2352512626001463"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.02.049","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful methotrexate rescue following antibody-mediated infliximab failure for treatment-refractory hidradenitis suppurativa","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2026.02.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}